Sienna Biopharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNNAQ research report →
Companywww.siennabio.com
Sienna Biopharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin.
- CEO
- David E. I. Pyott
- IPO
- 2017
- Employees
- 13
- HQ
- Westlake Village, CA, US
Price Chart
Valuation
- Market Cap
- $3.09K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.78%
- ROIC
- -92.02%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-73,314,000 · -45.05%
- EPS
- $-3.59 · 30.83%
- Op Income
- $-76,498,000
- FCF YoY
- -49.26%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.61
- Avg Volume
- 3.60K
Get TickerSpark's AI analysis on SNNAQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SNNAQ Coverage
We haven't published any research on SNNAQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SNNAQ Report →